All Articles by Author:

Jamie Kang

Effects of Local Anesthetics on Yield and Differentiation of Synovial Mesenchymal Stem Cells

[Scientific Reports] Scientists investigated whether clinically relevant concentrations of lidocaine and ropivacaine affect synovial MSC proliferation and differentiation.

Physical Differentiation of Adipose-Derived Mesenchymal Stem Cells Into Pancreatic Beta-Like Cells Using Cell-Imprinting and Evaluation of Insulin Production

[Adipocyte] Researchers physically induced the differentiation of rat adipose-derived mesenchymal stem cells into β-like cells using the cell-imprinting technique.

Umbilical Cord Mesenchymal Stem Cells and Wnt Pathway Modulation: A Novel Therapy for Liver Cirrhosis and Steatosis

[Tissue Engineering and Regenerative Medicine] Umbilical cord mesenchymal stem cells were used to treat cirrhosis, ranging from end-stage to early stages, in methionine-deficient rats by modulating the Wnt pathway.

Exosomal Mir-451a Derived from Bone Marrow Mesenchymal Stem Cells Inhibits Macrophage M1 Polarization through the MIF/CD74 Signaling Pathway to Alleviate Acute Lung Injury

[Immunological Investigations] Researchers investigated the role of bone marrow MSC-Exos in acute lung injury through the regulation of macrophage polarization.

Therapeutic Efficacy of Mesenchymal Stem Cells (MSCs) on Alzheimer’S Disease: Review of Clinical Results

[Tissue Engineering and Regenerative Medicine] Investigators evaluate the therapeutic effects of MSCs on Alzheimer's disease patients through a review of clinical trial literature.

SMYD2-Mediated Methylation of STAT1 Protects against Hepatic Ischaemia/Reperfusion Injury by Blocking JAK-STAT1 Signaling Pathways

[Gut] Investigators identified SMYD2, SET and MYND domain Containing 2 (SMYD2) as a critical regulator of signal transducers and activators of transcription 1 (STAT1) and investigated the mechanistic basis of SMYD2-mediated post-translational modifications in modulating STAT1 function during hepatic ischaemia/reperfusion.

Popular

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia

[New England Journal of Medicine] Investigators enrolled patients from a compassionate-use program and those from a Phase I study who had primary multirefractory autoimmune hemolytic anemia. Each patient received a single infusion of autologous CD19 CAR T cells.

CD4+ T Cells Mediate CAR-T Cell-Associated Immune-Related Adverse Events after BCMA CAR-T Cell Therapy

[Nature Medicine] Among 198 patients treated with ciltacabtagene autoleucel or idecabtagene vicleucel, 27 developed CAR T cell therapy-associated immune-related adverse events (CirAEs). This included one remarkable case with three distinct CirAEs in association with an extreme CD4+ CAR T cell expansion.

Contaminating Plasmid Sequences and Disrupted Vector Genomes in the Liver following Adeno-Associated Virus Gene Therapy

[Nature Medicine] Scientists conducted a case study of a child with spinal muscular atrophy type 1 experiencing substantial hepatitis after receiving onasemnogene abeparvovec, undertaking long- and short-read metagenomic sequencing of liver tissue.